SCHEMBL17679386

SCHEMBL17679386

C=C[C@H](OC(C)C)[C@@H](/C=C\COC(=O)c1ccccc1)OC(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.41
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
TK1 P04183 1/20 0.40
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17679392 0.81 KMT2A (0.48) ALDH1A1LMNACYP3A4TK1ADRB2
SCHEMBL17679376 0.81 KMT2A (0.50) MAPK1HIF1AALDH1A1LMNACYP3A4
SCHEMBL16254156 0.78 LMNA (0.46) MAPK1ALDH1A1LMNACYP3A4TK1
SCHEMBL17679373 0.77 ALDH1A1 (0.49) MAPK1HIF1AALDH1A1LMNACYP3A4
SCHEMBL17886498 0.76 ALDH1A1 (0.44) MAPK1HIF1AALDH1A1LMNACYP3A4
Benzene SCHEMBL28207781 0.74 CYP3A4 (0.69) MAPK1HIF1AALDH1A1LMNACYP3A4
SCHEMBL21007 0.74 CYP3A4 (0.69) MAPK1HIF1AALDH1A1LMNACYP3A4
SCHEMBL28343462 0.74 CYP3A4 (0.69) MAPK1HIF1AALDH1A1LMNACYP3A4
SCHEMBL8522570 0.73 TDP1 (0.61) MAPK1HIF1AALDH1A1LMNATK1
SCHEMBL8522569 0.73 TDP1 (0.61) MAPK1HIF1AALDH1A1LMNATK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160101414-A1 HIGHLY Z-SELECTIVE AND ENANTIOSELECTIVE RING OPENING/CROSS METATHESIS CATALYZED BY A RESOLVED STEREOGENIC-AT-RU COMPLEX CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160101414-A1 HIGHLY Z-SELECTIVE AND ENANTIOSELECTIVE RING OPENING/CROSS METATHESIS CATALYZED BY A RESOLVED STEREOGENIC-AT-RU COMPLEX ZFR, ZDHHC7, ORC3 MAPK1 4664/4885HIF1A 4488/4885ALDH1A1 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.